CClinicalTrials.gg
TerminatedNCT06200480Updated Apr 13, 2026

Nurse Intervention Trial

An interventional study of Telephone by nurse in Migraine, Chronic Tension-Type Headache and Cluster Headache, sponsored by Norwegian University of Science and Technology. Terminated at 1 site in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Treatment

Why this study was terminated
Based on ethical considerations arising from the interim analyses, the study was terminated before the planned sample size of 400 participants was reached
Phase
Not applicable
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This randomized open-label prospective study focus on headache patients initiating preventive treatment, where the treating physician identifies a need for follow-up visits in specialized healthcare. The study will clarify whether the implementation (compliance) and overall satisfaction of the patient are better with follow-up by a headache nurse compared to standard follow-up. Patients with signed written consent will be randomised to either group a: Telephone calls from nurse after two and 6 week or B. Patient-initiated follow-up by their general practitioner.

Read the detailed description

Potential patients suitable for this study must have undergone a regular consultation with a neurologist before. This consultation includes neurological and somatic examinations, diagnosis of the type of headache based on medical history, review of a completed headache diary, and any additional conducted examinations. The consultation will also involve an assessment of the possible initiation of preventive treatment. A selection of these patients will be prescribed electronic prescriptions for at least one previously untried type of preventive medication. During the consultation, patients will receive oral and written information about the dosage and expected possible side effects of the preventive medication. Those eligible for beta-blocker initiation will undergo an electrocardiogram (EKG) after the consultation. After completing the consultation, eligible patients will receive written and oral information about the study.

Those who provide consent to participate will, during subsequent registration with the secretaries at the neurological outpatient clinic immediately after the consultation, be randomized to one of two follow-up options (A or B) for further monitoring in the coming months until the scheduled follow-up, set at approximately 3 months, or later if there is a shortage of available appointments.

Group A will be followed up by a headache nurse through telephone consultations on at least two occasions shortly after the initiation of preventive medicine. Participants in this group will be invited to a planned final follow-up appointment after approximately 3 months with a neurologist.

Group B will have patient-managed follow-up with a planned final follow-up appointment after approximately 3 months. Participants will pick up the prescribed medication and contact their general practitioner or the neurological outpatient clinic by a study-specific email if they need advice from a neurologist.

02

Conditions studied

  • Migraine
  • Chronic Tension-Type Headache
  • Cluster Headache
  • Hemicrania Continua
03

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • One of the following headache diagnoses based on the International Classification of Headache Disorders, third edition (ICDH3): G44.2 Chronic tension-type headache and/or G43 Episodic and chronic migraine, G44.0 Episodic and chronic cluster headache, G44.8 Hemicrania Continua
  • Indication for preventive medication where there is at least one alternative with the need for follow-up assessment of effectiveness.

Exclusion criteria

Exclusion Criteria:

  • Uncertain headache diagnosis.
  • Need further investigation after the initial consultation.
  • Lack of understanding of information provided in Norwegian, both verbally and in writing.
  • Inability to keep a digital headache diary.
  • Need treatment of other comorbid conditions requiring follow-up in specialized healthcare.
  • Treatment with Onabotulinumtoxin A or Calcitonin-gene-related Peptide (CGRP) inhibitors given with three months intervals
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Active comparator
    Telephone by nurse

    The headache patients will be contacted by nurse by phone after approximately 2 week and 6 week after start of preventive medical treatment. The patient will have a follow-up visit by neurologist after 3 months.

    Other: Telephone by nurse

  • No intervention
    Patient-initiated follow-up

    The headache patient contact their general practitioner (GP) and/or the neurologist by a study-specific email if they have questions regarding the preventive medical treatment

Interventions

  • OtherTelephone by nurse

    Patient-initiated follow-up at week 2 and 6

05

What researchers measure

Primary outcomes

  1. Compliance

    number of participants who have carried out the prescribed preventive treatment, as in minimum duration of two months after the initial visit

    Time frame: 2 months

Secondary outcomes

  1. Number of days to at least a 30% reduction

    Number of days from inclusion to at least a 30% reduction erate to severe headache compared to in the frequency in the last month before the initial consultation

    Time frame: 3 months

  2. Responders

    Numbers of responders defined as\> 50% decrease in headache days compared to in the frequency in the last month before the initial consultation

    Time frame: 3 months

06

Study locations

1 site
  • St. Olavs Hospital HF
    Trondheim, 7489, Norway
07

References and documents

Study documents

  • Study protocol · Nov 11, 2022
  • Informed consent form · Jan 25, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Publication by home page of NorHead

Supporting information: Study protocol, Sap, Icf

08

Registry details

Key details

Study ID
NCT06200480
Lead sponsor
Norwegian University of Science and Technology
Collaborators
Haukeland University Hospital, Oslo University Hospital, St. Olavs Hospital
Responsible party
Sponsor
First posted
Jan 11, 2024
Start date
Apr 21, 2023
Primary completion
Jan 21, 2026
Completion
Jan 31, 2026
Last update
Apr 13, 2026

Study contacts

Geir Braathen
study chair · St. Olavs Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion